LNbits, a Lightning Network wallet platform, ordered all server operators to shut down immediately after multiple security breaches on Nov. 8, 2026. Attackers exploited vulnerabilities to steal over 2 million satoshis from a Telegram tipping service, prompting developers to prepare urgent security patches expected within 24 to 48 hours. The incident highlights ongoing security challenges in Lightning Network infrastructure, with LNbits suspending hosted services until fixes are implemented to prevent further losses. Operators are advised to keep systems offline until the patches are verified.
The Lightning Network security scare involving LNbits servers provides context for cryptocurrency market activity. For readers following digital assets, here is Pluang's market snapshot as of Nov 09, 2026 02:21 WIB: out of 50 major cryptocurrencies priced on Pluang, 8 rose and 41 fell today. Notable movers include ENJ (Enjin Coin) at Rp410 with a -3.27% change and 100% buy order activity, VET (VeChain) at Rp93 down 3.11% with 55% sell orders, and NEO (Neo) at Rp32,947 down 3.11% with 100% buy orders.
NVIDIA's Board of Directors has started an independent investigation after reports that CEO Jensen Huang was targeted by a foreign intelligence operation. The inquiry, led by independent directors and external counsel, aims to ensure no national secu...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
